Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

[AMS] Clinical Pharmacology & Therapeutics > S8) NSAIDs > Flashcards

S8) NSAIDs Flashcards

1
Q

What is the principal action of non-steroidal anti-inflammatory drugs?

A

Principle action – key enzymes in prostaglandin synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the three primary therapeutic effects of NSAIDs?

A
  • Analgesia
  • Anti-Inflammatory
  • Antipyretic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why do NSAIDs commonly have short half lives?

A

Short half lives allows fine control of the signalling response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How are prostaglandins synthesised?

A

Prostaglandins are synthesised from arachidonic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Identify two types of prostaglandins

A
  • Prostacyclins
  • Thromboxanes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the prostaglandin synthesis pathway

A

Prostaglandins are synthesised from cell membrane phospholipids and arachidonic acid and thereafter catalysed by COX-1/2 to produce specific PG enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PG ‘E’ is the most important in mediating the inflammatory response.

Identify four of its functions

A
  • Vasodilation
  • Hyperalgesia
  • Fever
  • Immunomodulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PG synthesis by COX -1 has major cytoprotective role in three locations.

Identify them

A
  • Gastric mucosa
  • Myocardium
  • Renal parenchyma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the half life of PG and what is the significance of this for NSAIDs?

A
  • PG t1/2 short (10 mins) – need constant synthesis
  • Due to its constitutive expression, most ADRs caused by NSAIDs are due to COX-1 inhibition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What induces COX-2 expression and where is it expressed?

A
  • COX-2 expression induced by inflammatory mediators such as bradykinin
  • COX-2 appears to be constitutively expressed in parts of the brain and kidney
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do the main therapeutic effects of NSAIDs occur?

A

Main therapeutic effects of NSAIDs occur via COX-2 inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Illustrate how differences in COX-1 and COX-2 tunnel for selective inhibition by different NSAIDs

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Explain prostaglandin binding with receptors

A
  • Prostaglandins bind with GPCRs
  • Specific actions depend on PG receptor types

For PG E, at least four main types: EP 1-4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

In four steps, describe how prostaglandins act as inflammatory response mediators

A

⇒ Range of autacoids and prostanoids released from local tissues/blood vessels post injury

⇒ Autacoid release also induces expression of COX-2

⇒ Synergise with other autacoids (bradykinin/histamine)

⇒ PGs act as potent vasodilators & synergise permeating effects of bradykinin/histamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

State the effect of prostaglandin release post injury at the following receptors:

  • EP2 receptor Gs
  • EP1 receptor Gq
A
  • EP2 receptor Gs – ↑ vasodilation
  • EP1 receptor Gq – ↑ peripheral nociception
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

With regards to sensitising peripheral nociception, describe the three effects of GPCR activation by EP1

A
  • Increased neuronal sensitivity to bradykinin
  • Inhibition of K+ channels
  • Increased Na+ channels sensitivity

All act to increase afferent ‘C’ fibre activity (carry pain stimuli)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In four steps, expain how peripheral sensitisation occurs

A

⇒ EP 1 binding leads to ↑ ‘C’ fibre activity

⇒ ↑ intracellular [Ca2+]

⇒ Neurotransmitter release

⇒ Other autacoids involved to ↑ sensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

In terms of nociception, illustrate the relationship between allodynia and hyperalgesia

A
  • Allodynia is pain due to a stimulus that does not usually provoke pain
  • Hyperalgesia is increased pain from a stimulus that usually provokes pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

In four steps, explain how sensitising central nociception occurs

A

⇒ Increased sustained nociceptive signalling peripherally ↑ cytokine levels in dorsal horn cell body

⇒ ↑ COX-2 synthesis and ↑ PGE<strong>2</strong> synthesis

⇒ PGE2 acts via local EP2 receptor (Gs type)

⇒ ↑ sensitivity and discharge rate of secondary interneurones

20
Q

In four steps, explain how prostaglandins lead to a state of pyrexia

A

⇒ Bacterial endotoxins stimulate macrophage release of IL-1

⇒ IL-1 stimulates PGE2 synthesis within hypothalamus

⇒ PGE2 acts via EP3 receptor (Gi type)

⇒ ↑ heat production and ↓ heat loss

21
Q

The main therapeutic effects achieved via COX-2 inhibition.

Briefly, explain how this occurs

A
  • Pharmacological action for nearly all NSAIDs via competitive inhibition of COX-1 and COX-2
  • Occupation of COX-1 /2 hydrophobic channel by NSAID competes with AA site occupation
22
Q

How are NSAIDs administered?

A

Typically given orally but many topical preparations for soft tissue injury

23
Q

Which pharmacokinetics pattern do NSAIDs illustrate?

A

Linear pharmacokinetics within therapeutic dose range

24
Q

There are two groups of NSAIDs according to half lives.

Identify them

A
  • T1⁄2 < 6hrs
  • T1⁄2 >10 hrs
25
Q

How are NSAIDs transported in the blood?

A

Many heavily bound to plasma protein (90-99%)

26
Q

Describe the therapeutic use of NSAIDs as an anti-inflammatory

A

Very wide use in musculoskeletal disorders – rheumatoid / osteoarthritis

27
Q

Describe the therapeutic use of NSAIDs as an analgesic

A
  • Used for mild to moderate pain accompanying many disease states
  • Universal use in Hospitals / OTC
28
Q

Inhibition of COX-1 constitutive PG synthesis leads to many side effects.

Indicate which patient group this usually affects

A

Long term use in elderly – particularly associated with iatrogenic morbidity and mortality

29
Q

Renal ADRs occur in compromised individuals with HRH or hypovolaemia.

What is HRH?

A
  • Heart failure
  • Renal disease
  • Hepatic cirrhosis
30
Q

The major ADRs are seen in stomach /GI tract.

Identify some

A
  • Stomach pain
  • Nausea
  • Heartburn
  • Gastric bleeding
  • Ulceration
31
Q

Explain why a gastric ADR can occur by the selective inhibition of COX-1

A

Gastric COX-1 PGE2 stimulates cytoprotective mucus secretion throughout GI tract, reduce acid secretion and promote mucosal blood flow

32
Q

Explain why a renal ADR can occur due to NSAIDs

A
  • PGE2 and PGI2 maintain renal blood flow
  • If reduced by NSAIDs then GFR decreases – further risk of renal compromise (especially neonates/elderly)
33
Q

Apart from GI and renal symptoms, identify some other NSAID ADRs

A
  • Vascular – decreased bleeding time, bruising haemorrhage
  • Hypersensitivity – skin rashes, bronchial asthma
  • Rare serious brain/liver injury – usually in viral infections treated with aspirin risk of damage
34
Q

What are the therapeutic benefits from combining NSAIDs with low dose opiates?

A
  • Extends therapeutic range for treating pain
  • Reduces ADRs seen with opiates alone
35
Q

Identify three highly protein bound drugs affected by NSAIDs

A
  • Sulphonylurea
  • Warfarin
  • Methotrexate
36
Q

What is the effect of NSAIDs given in combination with aspirin?

A

NSAIDs + low dose Aspirin – compete for COX-1 binding sites and may interfere with cardioprotective action of Aspirin

37
Q

What is the result of multiple NSAIDS given in combination?

A
  • Increase risk of ADRs – often occurs due to self medication with NSAIDs
  • Affect each others PK/PDs due to competition for plasma protein binding sites
38
Q

Describe how aspirin acts uniquely in the body

A
  • Only NSAID to irreversibly inhibit COX enzymes by acetylation
  • T1⁄2 < 30 minutes rapidly hydrolysed in plasma to salicylate
39
Q

Why is paracetamol a unique non NSAID?

A

Paracetamol is a unique ‘non NSAID’ as it has virtually no anti-inflammatory action – more of a NOAD (non-opiate anagelsic drug)

40
Q

When is paracetamol used?

A

Paracetamol is very effective for mild/moderate analgesia and fever

41
Q

What is the therapeutic dose for paracetamol?

A

Therapeutic dose: 8 x 500 mg tablets/day

42
Q

In normal doses, paracetamol displays linear pharmacokinetics.

How is it metabolised?

A
  • Mainly Phase II Conjugation – Glucoronide 60%, Sulphate 30%
  • Some Phase 1 Oxidation – NAPQI 10%
43
Q

NAPQI is very reactive and toxic.

How is it detoxified?

A
  • At normal doses, NAPQI is detoxified by Phase II conjugation with Glutathione
  • Linear detoxification step limited by availability of Glutathione
44
Q

What is a toxic dose of paracetamol?

A

Single doses > 10 g (20 tablets) potentially fatal

45
Q

At high doses, paracetamol pharmacokinetics become zero order.

Describe paracetamol metabolism at high doses

A
  • First step Phase II metabolism saturated
  • ↑ Phase I production of NAPQI
  • Phase II conjugation of NAPQI with glutathione rate limited – also saturated
46
Q

Paracetamol overdoses are time dependent – delayed hepatoxic effects peak 72 - 96 hrs post ingestion.

How can this be treated?

A
  • 0-4hrs – activated charcoal orally reduce uptake by 50-90%
  • 0-36 hrs – start N-Acetylcysteine IV
  • Methionine orally (if NAC cannot be given promptly)

[AMS] Clinical Pharmacology & Therapeutics (29 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions